Ontology highlight
ABSTRACT: Background
HMGCR(3-Hydroxy-3-methylglutaryl coenzyme A reductase), the direct target of statin inhibition, undergoes alternative splicing of exon 13, which encodes part of the statin-binding domain of the enzyme. We hypothesized that HMGCR alternative splicing might be related to the interindividual variation in plasma low-density lipoprotein cholesterol response to statin treatment.Methods and results
We measured mRNA expression of both the full-length and the alternatively spliced HMGCR transcript lacking exon 13 (HMGCRv_1) in 170 simvastatin-incubated immortalized lymphocyte cell lines derived from participants in the Cholesterol and Pharmacogenetics (CAP) study who were treated with simvastatin 40 mg/d for 6 weeks. Greater upregulation of HMGCRv_1 in vitro was significantly correlated (P
SUBMITTER: Medina MW
PROVIDER: S-EPMC2720070 | biostudies-literature | 2008 Jul
REPOSITORIES: biostudies-literature
Medina Marisa Wong MW Gao Feng F Ruan Weiming W Rotter Jerome I JI Krauss Ronald M RM
Circulation 20080616 4
<h4>Background</h4>HMGCR(3-Hydroxy-3-methylglutaryl coenzyme A reductase), the direct target of statin inhibition, undergoes alternative splicing of exon 13, which encodes part of the statin-binding domain of the enzyme. We hypothesized that HMGCR alternative splicing might be related to the interindividual variation in plasma low-density lipoprotein cholesterol response to statin treatment.<h4>Methods and results</h4>We measured mRNA expression of both the full-length and the alternatively spli ...[more]